Article
UPDATED: Biogen spotlights a pair of painful pipeline setbacks as aducanumab showdown looms at the
Rating:
0.0
Views:
157
Likes:
1
Library:
1
Biogen has flagged a pair of setbacks in the pipeline, spotlighting the final failure for a one-time top MS prospect while scrapping a gene therapy for SMA after the IND was put on hold due to toxicity. Both failures will raise the stakes even higher on aducanumab, the Alzheimer's drug
Rate This Post
-
Education
-
Communication
-
Entertainment
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value